VIVXF News and Press, Avivagen From 04/08/22

Record Year of Progress for OxC-beta TM Adoption Worldwide Supply agreement with AB Vista in United States, Brazil and Thailand compliments existing partnerships in Asia and Mexico Continued positive animal trial results leading to orders, new customer wins...

1Q22 Results. Avivagen reported revenue of $271,157 (all figures in Canadian $) in the quarter, up from $261,987 last year, and compared to our $300,000 estimate. Net loss for the quarter was $1.6 million, or $0.03 per share versus a net loss of $1.3 million, or $0.03 per share, in the first q...

Avivagen press release (OTCQB:VIVXF): Q4 loss of C$1.55M. Revenue of C$0.27M (+3.8% Y/Y). For further details see: Avivagen loss of C$1.55M, revenue of C$0.27M

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

The New Offering. Avivagen's management announced yesterday the intention to complete a private placement financing of secured debentures. The gross proceeds of this financing will total up to CAD$6.5 million and will close on March 28, 2022. Bloom Burton Securities is acting as the agent in t...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

Vietnam Approval. Yesterday, Avivagen announced a major milestone with the approval for use of OxC-beta in Vietnam. Vietnam represents the largest feed market in Southeast Asia, according to a report by the US Grains Council, which indicates total annual feed consumption of over 32 MMT in 2020...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

4Q21 Results. Avivagen's management reported revenue of $368,504 (all figures in Canadian $) in the quarter, up from $287,897 last year, but down from our estimated revenue of $1.4 million. The miss is mostly due to a Philippines order that will be recognized in the first quarter of fiscal 202...